2XJ0 Stock Overview
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Avalon GloboCare Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.44 |
| 52 Week High | US$5.33 |
| 52 Week Low | US$4.50 |
| Beta | 0.68 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2XJ0 | DE Real Estate | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.8% | -1.5% |
| 1Y | n/a | 5.3% | 0.9% |
Return vs Industry: Insufficient data to determine how 2XJ0 performed against the German Real Estate industry.
Return vs Market: Insufficient data to determine how 2XJ0 performed against the German Market.
Price Volatility
| 2XJ0 volatility | |
|---|---|
| 2XJ0 Average Weekly Movement | n/a |
| Real Estate Industry Average Movement | 5.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2XJ0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 2XJ0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 6 | David Jin | www.avalon-globocare.com |
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People’s Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.
Avalon GloboCare Corp. Fundamentals Summary
| 2XJ0 fundamental statistics | |
|---|---|
| Market cap | €28.36m |
| Earnings (TTM) | -€10.93m |
| Revenue (TTM) | €1.10m |
25.7x
P/S Ratio-2.6x
P/E RatioIs 2XJ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2XJ0 income statement (TTM) | |
|---|---|
| Revenue | US$1.19m |
| Cost of Revenue | US$913.65k |
| Gross Profit | US$280.26k |
| Other Expenses | US$12.13m |
| Earnings | -US$11.85m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.19 |
| Gross Margin | 23.47% |
| Net Profit Margin | -992.32% |
| Debt/Equity Ratio | 99.5% |
How did 2XJ0 perform over the long term?
See historical performance and comparison